高危高级别非肌层浸润性膀胱癌根治性膀胱切除术对比膀胱内BCG的随机对照BRAVO可行性研究
该研究为双臂前瞻性多中心随机可行性研究,纳入适合两种治疗的BCG初治高危高级别NMIBC患者,评估随机比较mBCG与RC的可行性。共筛查407例,185例被接洽,51例(27.6%)同意,50例随机分组。结论为随机对照试验招募困难,约10%患者为致死性疾病可能更适合初始根治治疗,而许多患者适合保留膀胱并维持诊断前生活质量。
要点
- 随机比较mBCG与RC的试验招募具有挑战性。
- 约10%高危高级别NMIBC患者为致死性疾病,可能更适合初始根治治疗。
- 许多患者适合保留膀胱并可能维持诊断前生活质量。
核心结论
- 随机对照比较mBCG与RC的试验将难以招募。
- 约10%高危高级别NMIBC患者为致死性疾病,可能更适合初始根治治疗。
- 相反,许多患者适合保留膀胱并可能维持诊断前生活质量。
研究设计与样本
- 双臂前瞻性多中心随机研究,旨在确定BCG初治患者的可行性。
- 参与者为新发高危高级别NMIBC且适合两种治疗。
- 随机分配按年龄、性别、中心、分期、原位癌存在及既往低危膀胱癌分层。
- 定性工作研究如何保持均势。
- 主要结局为筛查、合格、招募和随机分配的患者数。
主要发现
- 筛查407例,接洽185例,51例(27.6%)同意,1例未继续,50例按1:1随机。
- mBCG组25例中23例(92.0%)接受mBCG,4例诱导后为NMIBC,3例4个月时为NMIBC,4例接受RC。
- 研究结束时mBCG组2例患者发生转移性膀胱癌。
- RC组20例中20例(80.0%)接受膀胱切除术,其中5例(25.0%)无肿瘤,13例(65.0%)为高危高级别NMIBC,2例(10.0%)标本有肌层浸润。
- 随访时RC组所有患者无病。
临床怎么用
- 临床决策时应考虑约10%高危高级别NMIBC患者为致死性疾病,可能更适合初始根治治疗。
- 许多高危高级别NMIBC患者适合保留膀胱并可能维持诊断前生活质量。
局限性
- 该研究为可行性研究,样本量小(50例随机),主要结局为招募可行性而非疗效比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: High-grade nonmuscle invasive bladder cancer (HRNMIBC) is a heterogeneous disease. Treatments include intravesical maintenance Bacillus Calmette-Guerin (mBCG) and radical cystectomy (RC). We wanted to understand whether a randomized trial comparing these options was possible. MATERIALS AND METHODS: We conducted a two-arm, prospective multicenter randomized study to determine the feasibility in Bacillus Calmette-Guerin-naive patients. Participants had new high-risk HRNMIBC suitable for both treatments. Random assignment was stratified by age, sex, center, stage, presence of carcinoma in situ, and prior low-risk bladder cancer. Qualitative work investigated how to maintain equipoise. The primary outcome was the number of patients screened, eligible, recruited, and randomly assigned. RESULTS: We screened 407 patients, approached 185, and obtained consent from 51 (27.6%) patients. Of these, one did not proceed and therefore 50 were randomly assigned (1:1). In the mBCG arm, 23/25 (92.0%) patients received mBCG, four had nonmuscle invasive bladder cancer (NMIBC) after induction, three had NMIBC at 4 months, and four received RC. At closure, two patients had metastatic BC. In the RC arm, 20 (80.0%) participants received cystectomy, including five (25.0%) with no tumor, 13 (65.0%) with HRNMIBC, and two (10.0%) with muscle invasion in their specimen. At follow-up, all patients in the RC arm were free of disease. Adverse events were mostly mild and equally distributed (15/23 [65.2%] patients with mBCG and 13/20 [65.0%] patients with RC). The quality of life (QOL) of both arms was broadly similar at 12 months. CONCLUSION: A randomized controlled trial comparing mBCG and RC will be challenging to recruit into. Around 10% of patients with high-risk HRNMIBC have a lethal disease and may be better treated by primary radical treatment. Conversely, many are suitable for bladder preservation and may maintain their prediagnosis QOL.
引用
- Catto JWF, Gordon K, Collinson M, et al. Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study. J Clin Oncol. 2020. PMID: 33332191. doi:10.1200/JCO.20.01665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。